{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-030315","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-09-14T20:00:15+00:00","discovered_at":"2026-09-14T20:02:00.324969+00:00","generated_at":"2026-09-14T20:02:43.780424+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Moleculin to present new Annamycin data at AACR pancreatic cancer conference and two European scientific meetings","bullets":["Three September 2026 presentations examine Annamycin tissue distribution, topoisomerase II inhibition, and CD8+ T cell-mediated antitumor activity.","Presentations include Sept 25-28 AACR Pancreatic Cancer Conference in San Diego, plus Polish meetings on Sept 9-12 and Sept 14.","Waldemar Priebe (MD Anderson) presents two talks; Angela Alistar (Atlantic Health) presents AACR abstract on pancreatic cancer.","MIRACLE trial in relapsed/refractory AML remains the primary development focus and basis of near-term milestones.","AACR abstract under embargo until publication on Sept 25, 2026 at 1:00 p.m. ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-030315","json":"https://secwatch.observer/filing/0001437749-26-030315.json","markdown":"https://secwatch.observer/filing/0001437749-26-030315.md","text":"https://secwatch.observer/filing/0001437749-26-030315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926030315/0001437749-26-030315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926030315/mbrx20260911_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T20:02:43.780424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}